Navigation Links
LIVALO(R) Demonstrates Sustained, Long-Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Date:9/1/2009

emia and Hypercholesterolemia

Dyslipidemia refers to abnormal levels of fatty substances in the blood, or a disorder of the production or breakdown process of lipoprotein. Dyslipidemia may be marked by an elevation of TC, LDL-C, and TG concentrations and a decrease in HDL-C in the blood. An elevated level of cholesterol in the blood is called hypercholesterolemia, commonly referred to as high cholesterol.

Dyslipidemia is well established as one of the strongest independent predictors of cardiovascular morbidity and mortality. Despite the availability of treatments in the United States, there is still a need for better control of and treatment for dyslipidemia. According to the American Heart Association, approximately one out of every three American adults has an LDL-C level of 130 mg/dL or higher, which is a major risk factor for coronary heart disease (CHD) and stroke. In addition, less than half of patients who qualify for any kind of lipid-modifying treatment( )for CHD risk reduction are receiving it, and only about( )one-third of patients who are on treatment are achieving their LDL-C ( )goals.

About Kowa Company Ltd., Kowa Pharmaceuticals America, Inc. and Kowa Research Institute, Inc.

Kowa Company, Ltd. (KCL) is a privately held multinational company headquartered in Nagoya, Japan. Established in 1894, KCL is actively engaged in various manufacturing and commercial activities in the fields of pharmaceutical, life science, information technology, textiles, machinery and various consumer products. KCL's pharmaceutical division is focused on cardiovascular therapeutics, with sales of the company's flagship product, LIVALO, totaling $340 million (12% market share) in Japan during the 2008 fiscal year and expected to exceed $500 million in the near future.

Kowa Pharmaceuticals America, Inc. (KPA) is a specialty pharmaceutical company focused primarily in the
'/>"/>

SOURCE Kowa Company Ltd., Kowa Pharmaceuticals America, Inc., and Kowa Research Institute, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia
2. Noteworthy Medical Systems Demonstrates National Health Information Network (NHIN) Interoperability
3. Recently Published Study Demonstrates Pharmacokinetic Advantages of ENDOMETRIN(R) Over Crinone(R) for Progesterone Supplementation
4. Advanced Life Sciences Restanza Demonstrates Efficacy in Treating Anthrax Infection
5. Survey Demonstrates Marin County Residents Support Locally Owned and Operated Marin General Hospital
6. EVEREST Data Demonstrates Acute Reduction of Mitral Regurgitation Without Procedural Mortality in Patients Treated With the MitraClip(R) Therapy
7. VivaGel(R) Demonstrates Anti-HIV and Herpes Activity Following Human Administration
8. CAeHC Demonstrates NHIN-enabled Gateways Among Five California Health Information Exchanges
9. Study demonstrates the anti-inflammatory properties of pine bark extract
10. Study Demonstrates the Anti-Inflammatory Properties of Pine Bark Extract on Inflammatory Mediators COX-2 and 5-LOX
11. Analysis of drug-eluting stents data demonstrates safety, efficacy in on-and-off-label use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Portland, OR (PRWEB) March 02, 2015 ... its plan to remake American healthcare. Zoom will ... include 28 neighborhood clinics and advanced care studios ... mental health, emergency services, specialty care and outpatient ... provide on-demand access to almost all healthcare needs ...
(Date:3/2/2015)... Birmingham, Alabama (PRWEB) March 02, 2015 ... Alabama - In conjunction with Women in Construction Week ... in Construction, or NAWIC) and National Women’s History Month, ... and commitment positively affect the company and the construction ... the management team, to the dozens of roles in ...
(Date:3/2/2015)... Burns Engineering's Lab-to-Lab Calibration Service ... Standard Platinum Resistance Thermometers (SSPRTs) and industrial Resistance ... less . . . guaranteed. Their ... Code 200706-0), ISO 9001 and 17025 Certified and ... -196°C to 500°C, both ITS-90 and Callendar-van Dusen ...
(Date:3/2/2015)... The Workgroup for Electronic Data Interchange (WEDI), the ... IT to create efficiencies in healthcare information exchange, released ... The white paper by WEDI’s ICD-10 Testing Subworkgroup provides ... by focusing on primary considerations and steps for external ... 1, 2015 implementation date. Download the white paper ...
(Date:3/2/2015)... March 02, 2015 Representatives with ... has officially launched a multivitamin supplement that’s specifically ... product development for BNatrl, said the multivitamin, which ... Olympic and other world-class athletes. , "Being an ... this pure whole food multivitamin to improve my ...
Breaking Medicine News(10 mins):Health News:ZoomCare Announces 28-Location, On-Demand Neighborhood Health Campus 2Health News:ZoomCare Announces 28-Location, On-Demand Neighborhood Health Campus 3Health News:Robins & Morton Recognizes Women In Construction 2Health News:Burns Engineering Announces Quick-Turn Temperature Calibrations 2Health News:WEDI Releases New White Paper on ICD-10 Testing for Small Providers 2Health News:Bnatrl Launches Multivitamin Supplement for Runners 2
... Cost Saving Benefit Faces Eventual Elimination Without Relief ... support of President Obama,s pledge not to raise taxes on ... -- outside of the normal legislative process -- adopting provisions ... restrict the use of flexible spending accounts (FSAs) in order ...
... Oct. 14 New Enterprise Associates, Inc. (NEA), a leading ... has been promoted to General Partner. Dr. Viswanathan, who joined ... equity information technology investments, as well as the firm,s activities ... Principal. Dr. Torti joined NEA in 2007 and is focused ...
... Networks , the nation,s leading provider of physician office-based ... consumer purchase behavior, not just purchase intent, for OTC ... revenue and justify investments designed to capture market share, ... health messages to purchase volume. To address this need ...
... aged 70-79, the apparent association between light-to-moderate alcohol consumption ... not hold up after adjustments were made for characteristics ... education, and income. The authors of the ... American Geriatrics Society , say this suggests that life-style ...
... SAN DIEGO, Oct. 14 Cardium Therapeutics (NYSE Amex: ... Matrix Phase 2b clinical trial of Excellarate(TM) for the ... ulcers based on the Company,s Gene Activated Matrix (GAM) ... the Excellarate product candidate (GAM501, which is a combination ...
... Continuing its efforts to educate, inform, and empower ... patient-focused organization, is hosting its 25-minute live call-in show, ... Monday, October 19, 2009 at 6:00 PM on Channel ... frank discussion regarding Retail Health Clinics with Erin Buckley, ...
Cached Medicine News:Health News:Fight to Preserve Flexible Spending Accounts Moves to the House of Representatives 2Health News:Fight to Preserve Flexible Spending Accounts Moves to the House of Representatives 3Health News:NEA Promotes Ravi Viswanathan to General Partner and Names Frank Torti to Principal Post 2Health News:NEA Promotes Ravi Viswanathan to General Partner and Names Frank Torti to Principal Post 3Health News:Healthy Advice Networks Now Able to Track Consumer Purchase Behavior 2Health News:Healthy Advice Networks Now Able to Track Consumer Purchase Behavior 3Health News:'Beneficial' effects of alcohol? 2Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 2Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 3Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 4Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 5Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 6Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 7Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 8Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 9Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 10Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 11Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 12Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 13Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 14Health News:Retail Health Clinics - The Real Story 2
(Date:3/2/2015)... , March 2, 2015  CANTEL MEDICAL CORP. ... Andrew A. Krakauer , CEO, will be presenting at ... Investor Forum. The formal presentation is scheduled for 2:00 ... Grand Hyatt Hotel, New York . ... Senior VP-Corporate Development, will be available for separate one-on-one ...
(Date:3/2/2015)... For the past 15 years, there has been an average of ... (U.S. Census Bureau 2012). Of course, not every accident is severe ... quite a few where the car occupants can get stuck in ... release button or occupant injury. One may be ... lifetime but may still be "lucky" enough to come upon an ...
(Date:3/2/2015)... , March 2, 2015   Mast ... biopharmaceutical company, today announced preliminary findings from a ... a model of chronic, stable heart failure produced ... study was to examine the effects of repeat ... systolic and diastolic function. Consistent ...
Breaking Medicine Technology:New SuperVizor, an Automobile Escape Tool, Ensures the Safety of Drivers and Passengers on the Road 2Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 2Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 3Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 4Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 5Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 6
... in Poor Risk Frontline Elderly AML and in Combination with Cytarabine ... Call Scheduled for Tuesday, December 9 at 11:00 am ET to ... , SAN FRANCISCO , Dec. 7 ... the presentation of new data from two ongoing clinical trials demonstrating ...
... carisbamate, an,investigational compound recently filed with the FDA for ... 16 years of age and,older, was presented today during ... American Epilepsy Society. , ... efficacy, safety and tolerability of carisbamate as an,adjunctive treatment ...
Cached Medicine Technology:Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 2Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 3Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 4Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 5Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 6Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures 2Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures 3Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures 4Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures 5
... 4420 Colloid Osmometer. Rapid measurement of ... prediction of edema onset in clinical ... sample and reference chambers to simulate ... membrane in the establishment of osmotic ...
... Automated Cortisol assay with flexible ... workflow, Excellent correlation and agreement ... confidence,in assay performance, Standardized to ... Panels delivers assurance in,accuracy of ...
Quantitative determination of cortisol levels in serum and urine. Cross-reactivity with dexamethasone: 0.2% (suppression test).Time to first result: 30 minutes....
... IMMULITE 2500 is a high-throughput immunoassay ... ,of the IMMULITE 2000 with the important ... technology ,allows assays to be designed for ... times. ,This allows for critical assays such ...
Medicine Products: